Presidential symposium 1

LBA1 

Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study

Cortés, et al.

Conclusions

T-DXd demonstrated a highly statistically significant and clinically meaningful improvement in PFS vs T-DM1 in pts previously treated with trastuzumab and taxane for HER2+ mBC. These data confirm that T-DXd is tolerable with manageable toxicity and a significant improvement in ILD profile vs studies performed in more heavily pretreated pts. This study will lead to a paradigm shift in the treatment of HER2+ mBC.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA1.html.pdf

 

LBA2

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study

Colombo, et al.

Conclusions

Pembro + chemo provided statistically significant, clinically meaningful PFS and OS improvements in pts with persistent, recurrent, or metastatic cervical cancer, regardless of PD-L1 expression and concomitant bev use. Along with a manageable safety profile, these data suggest pembro + chemo ± bev may be a new standard of care for this population.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA2.html.pdf

 

LBA3

Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

J.J. Luke, et al.

Conclusions

Adjuvant pembrolizumab for resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo and was associated with significantly prolonged RFS and a favorable benefit-risk profile.

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2021_abstracts/LBA3.html.pdf